EXPEDITED DEFINITION
Expedited review studies are those minimal risk protocols that
do not need to be reviewed by the fully convened IRB (21
CFR 56.110; 45 CFR 46.110)
*They constitute 96% of the Yale
social/behavioral/educational IRB workload
*The approval criteria are the same as for the full
convened meeting
*The expedited reviewer can approve, SMR, or defer
approval but cannot disapprove (full board action only)
WHO REVIEWS?
Expedited review may be conducted by the following
individuals:
An IRB Chair
An experienced IRB member designated by the Chair
A regulatory analyst (IRB staff) who also serves as an
IRB member designated by the Chair
EXPEDITED REVIEW CATEGORIES
Federal regulations specify :
*The overall protocol must be minimal risk to even be considered for expedited review*
1. Research on drugs or devices for which an investigational new drug or investigational
device exemption is not required (e.g., approved drug; non-significant risk device)
2. Collection of blood samples from healthy individuals (limit on amount and frequency of
blood drawn)
3. Prospective collection of biological specimens by non-invasive means (examples given)
4. Collection of data using non-invasive procedures routinely employed in clinical practice
5. Research involving materials (data, records, etc.) that have been collected or will be
collected solely for non-research purposes.
6. Collection of data from voice, video, digital or image recordings made for research purposes
EXPEDITED REVIEW CATEGORIES-2
7. Research on individual or group characteristics or behavior (such as cultural beliefs, perception,
language) or research employing survey, oral history, program evaluation
8. Continuing review of research previously approved by the convened IRB, limited to the following:
Research is permanently closed to enrollment, all subjects have completed all
research interventions and the study is active only for long-term follow-up
Research where no participants have been enrolled and no added risks have been
identified
Research where the remaining research activity is limited to data analysis
9. Continuing review of research not conducted under an investigational new drug application or
investigational device exemption where the research does not other wise qualify for expedited
BUT the IRB has determined and documented at a convened meeting that the research
involves no greater than minimal risk and no additional risks have been identified.
RELATIONSHIP TO THE CONVENED MEETING
Federal regulations require IRB members be informed of
research proposals that have been approved under
the expedited process.
Every meeting agenda includes a list of the expedited
IRB review determinations that have been made in the
previous month. This includes those that have
undergone expedited review and those that were
determined to be exempt.
ADDITIONAL INFORMATION
See our website at http://www.yale.edu/hrpp/policies/index.html#IRBReview
Policy 100: Institutional Review Board (IRB) Review of Research Protocols Involving
Human Participants
Procedure 100 PR2: Expedited Review